A. Weltermann

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease

M. STAIN, Verena Schönauer, E Minar et al. · Journal of Thrombosis and Haemostasis · 2005 · 303 citations · Full text

Medicine, Hematology, Hemostasis +13

A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis

Hermine Agis, A. Weltermann, Christa Fonatsch et al. · Annals of Hematology · 2002 · 117 citations

Medicine, Hematology, Oncology +17

Comparison between idiopathic deep vein thrombosis of the upper and lower extremity regarding risk factors and recurrence

Daniel Lechner, Caspar Wiener, A. Weltermann et al. · Journal of Thrombosis and Haemostasis · 2008 · 111 citations · Full text

Medicine, Hematology, Surgery +15

Chemotherapy‐induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity

Daniel Lechner, Marietta Kollars, Paul A. Kyrle et al. · Journal of Thrombosis and Haemostasis · 2007 · 109 citations · Full text

Medicine, Cancer Biology, Chemotherapy +13